Literature DB >> 12013364

Atypical neuroleptic malignant syndrome associated with olanzapine.

Roy R Reeves1, Raphael A Torres, Vincent Liberto, Roy H Hart.   

Abstract

Neuroleptic malignant syndrome (NMS) is a potentially life-threatening adverse effect of antipsychotic agents. It generally is characterized by fever, altered mental status, rigidity, and autonomic dysfunction. A 53-year-old man developed NMS without rigidity while taking olanzapine. Such atypical cases may support either a spectrum concept of NMS or the theory that NMS secondary to atypical antipsychotics differs from that caused by conventional neuroleptics. More flexible diagnostic criteria than currently mandated by the the Diagnostic and Statistical Manual of Mental Disorders, Fourth Revision, may be warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12013364     DOI: 10.1592/phco.22.8.641.33211

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  5 in total

1.  Serum creatine kinase elevation as a possible complication of therapy with olanzapine.

Authors:  Evgeniy Perlov; Ludger Tebartz van Elst; Martin Czygan; Emanuel Bubl; Dieter Ebert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-10-22       Impact factor: 3.000

2.  A Rare Case of Myxedema Coma with Neuroleptic Malignant Syndrome (NMS).

Authors:  Siddharth Dixit; Manoj Kumar Dutta; Mayank Namdeo
Journal:  J Clin Diagn Res       Date:  2015-05-01

3.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

Review 4.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Atypical Neuroleptic Malignant Syndrome Precipitated by Clozapine and Quetiapine Overdose: A Diagnostic Challenge.

Authors:  David Choon Liang Teo; Hon Khuan Wong; Sheng Neng Tan
Journal:  Innov Clin Neurosci       Date:  2018-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.